Navigation Links
InterMune Appoints Angus C. Russell to Board of Directors
Date:10/31/2011

BRISBANE, Calif., Oct. 31, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Angus C. Russell, Chief Executive Officer of Shire plc, has been appointed to InterMune's Board of Directors.  Shire is a leading global biopharmaceutical company focused on meeting the needs of the specialist physician.

"Angus Russell has successfully led Shire's evolution to a leading global biopharmaceutical company with expertise in the development and commercialization of specialty medicines," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "We look forward to drawing on his experience as we execute the launch of Esbriet in Europe, prepare to launch Esbriet beyond Europe and advance our other programs targeted on pulmonary and fibrotic diseases."  

Angus Russell has served as Chief Executive Officer at Shire since June 2008.  He is also the Chairman of Shire's Leadership Team and was a lead member of the Shire Management Committee that devised and implemented Shire's long-term, focused business strategy.  Prior to his current role, Mr. Russell was Chief Financial Officer at Shire from 1999 to 2008.  

Previous to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca PLC.  In that role he was responsible for financial input into merger and acquisition activities, management of tax, legal and finance structure, investor relations, and the management of various financial risks.  Mr. Russell also held a number of positions within Zeneca Group PLC from 1993 until 1999, including Group Treasurer.  He is a chartered accountant, having qualified with Coopers & Lybrand (now PricewaterhouseCoopers LLP).

Mr. Russell is a member of the Board of Directors of Shire and also serves as a Member of the Advisory Board of Celtic Pharma Management L.P., a private equity advisement firm.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements  

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including statements related to the commercial launch of Esbriet and InterMune's clinical development plans.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 9, 2011 and other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune to Release Third Quarter Financial Results on November 3
2. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
5. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune Reports Third Quarter 2010 Financial Results
8. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
9. InterMune to Release Second Quarter Financial Results on July 27
10. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
11. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 Progra m ... trial of Oxitec , s mosquito in ... aegypti by 96 %   ... new plan to fight wild Aedes aegypti, the dangerous mosquito that ... the island of Grand Cayman .  MRCU, a global leader ...
(Date:5/5/2016)... , May 5, 2016 Research ... PET Imaging in Top 5 EU Markets"  report to their ... This report provides information on the current Positron Emission Tomography ... European Markets (T5 EU), which includes France ... , Spain and the ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 /PRNewswire/ ... the addition of the  "Europe Thalassaemia Market ... to their offering.       (Logo: ... research Europe Thalassaemia Market and Competitive Landscape ... Thalassaemia pipeline products, Thalassaemia epidemiology, Thalassaemia market ...
Breaking Medicine Technology:
(Date:5/5/2016)... Kansas (PRWEB) , ... May 05, 2016 , ... ... that some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian ... of red, green, and brown seaweeds. The pair observed that when photosynthetically active ...
(Date:5/5/2016)... MS (PRWEB) , ... May 05, 2016 , ... ... medical conditions and Make-A-Wish grants the most heartfelt wishes of these children. ... rounds of medical treatment. President and CEO of Make-A-Wish Mississippi, Brent Wilson ...
(Date:5/5/2016)... ... 2016 , ... Long Island’s fastest growing comprehensive eye care provider, North ... Kathleen Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage ... managing partner of North Shore Eye Care. , “We are extremely proud to ...
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ZAC Foundation ... new partnership to reach nearly 1 million children with important water safety messages before ... the leading cause of accidental death in children one to 6 years of age. ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week 2016, ... the United States to thank a nurse who's made a difference in their life. ... the American Red Cross of San Diego/Imperial Counties (up to $10,000) every time someone ...
Breaking Medicine News(10 mins):